DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

New peptide library paves the way for targeting elusive cancer factor MYC

Researchers developed a second-generation NTB bicyclic peptide library, identifying NT-B2R, a peptide that effectively targets MYC, a key factor in most human cancers, demonstrating its

January 8, 2024

Emory Healthcare to Pilot AI-Powered Virtual Inpatient Monitoring

What You Should Know: – Emory Healthcare partners with Andor Health to implement virtual patient observer technology to enhance safety interventions and reduce fall risks

November 7, 2023

CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. government on Tuesday announced a long-awaited “access

January 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.